Rivals of Genomic Health s Oncotype Dx Could Exploit Forerunner s Price, Other Limitations | GenomeWeb

Genomic Health's Oncotype Dx has a high profile in the molecular diagnostics market, and though the test is currently playing nearly unopposed, a number of rivals are using it as a blueprint of sorts to help them develop their own diagnostics for breast cancer recurrence.

During Cambridge Healthtech Institute's Tri-Conference last week in San Francisco, Genomic Health CEO Randy Scott spoke about the company's data validation procedure for the test. But Oncotype Dx isn't perfect, and the competition is trying to get fierce.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.